💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Axatilimab

CHEMBL4594608 Phase 4 अनुमोदित Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A monoclonal antibody that targets the CSF-1 receptor on macrophages, blocking a signaling pathway that promotes the tissue inflammation and fibrosis seen in chronic graft-versus-host disease. It is used in patients who have not responded to prior therapies.

चिकित्सीय क्षेत्र

Lymphoma Breast Cancer Leukemia

क्रिया का तंत्र

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

A monoclonal antibody that targets the CSF-1 receptor on macrophages, blocking a signaling pathway that promotes the tissue inflammation and fibrosis seen in chronic graft-versus-host disease. It is used in patients who have not responded to prior therapies.

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

Yes, Axatilimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594608. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.